ArticleJournal of clinical medicine2021

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes.

Christof Haensli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.